» Articles » PMID: 27151405

DrugGenEx-Net: a Novel Computational Platform for Systems Pharmacology and Gene Expression-based Drug Repurposing

Overview
Publisher Biomed Central
Specialty Biology
Date 2016 May 7
PMID 27151405
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The targeting of disease-related proteins is important for drug discovery, and yet target-based discovery has not been fruitful. Contextualizing overall biological processes is critical to formulating successful drug-disease hypotheses. Network pharmacology helps to overcome target-based bottlenecks through systems biology analytics, such as protein-protein interaction (PPI) networks and pathway regulation.

Results: We present a systems polypharmacology platform entitled DrugGenEx-Net (DGE-NET). DGE-NET predicts empirical drug-target (DT) interactions, integrates interaction pairs into a multi-tiered network analysis, and ultimately predicts disease-specific drug polypharmacology through systems-based gene expression analysis. Incorporation of established biological network annotations for protein target-disease, -signaling pathway, -molecular function, and protein-protein interactions enhances predicted DT effects on disease pathophysiology. Over 50 drug-disease and 100 drug-pathway predictions are validated. For example, the predicted systems pharmacology of the cholesterol-lowering agent ezetimibe corroborates its potential carcinogenicity. When disease-specific gene expression analysis is integrated, DGE-NET prioritizes known therapeutics/experimental drugs as well as their contra-indications. Proof-of-concept is established for immune-related rheumatoid arthritis and inflammatory bowel disease, as well as neuro-degenerative Alzheimer's and Parkinson's diseases.

Conclusions: DGE-NET is a novel computational method that predicting drug therapeutic and counter-therapeutic indications by uniquely integrating systems pharmacology with gene expression analysis. DGE-NET correctly predicts various drug-disease indications by linking the biological activity of drugs and diseases at multiple tiers of biological action, and is therefore a useful approach to identifying drug candidates for re-purposing.

Citing Articles

Drug repurposing for Alzheimer's disease from 2012-2022-a 10-year literature review.

Grabowska M, Huang A, Wen Z, Li B, Wei W Front Pharmacol. 2023; 14:1257700.

PMID: 37745051 PMC: 10512468. DOI: 10.3389/fphar.2023.1257700.


Transcriptomics for Clinical and Experimental Biology Research: Hang on a Seq.

Stokes T, Cen H, Kapranov P, Gallagher I, Pitsillides A, Volmar C Adv Genet (Hoboken). 2023; 4(2):2200024.

PMID: 37288167 PMC: 10242409. DOI: 10.1002/ggn2.202200024.


CREB3L2-ATF4 heterodimerization defines a transcriptional hub of Alzheimer's disease gene expression linked to neuropathology.

Roque C, Chung K, McCurdy E, Jagannathan R, Randolph L, Herline-Killian K Sci Adv. 2023; 9(9):eadd2671.

PMID: 36867706 PMC: 9984184. DOI: 10.1126/sciadv.add2671.


A novel chemo-phenotypic method identifies mixtures of salpn, vitamin D3, and pesticides involved in the development of colorectal and pancreatic cancer.

Issa N, Wathieu H, Glasgow E, Peran I, Parasido E, Li T Ecotoxicol Environ Saf. 2022; 233:113330.

PMID: 35189517 PMC: 10202418. DOI: 10.1016/j.ecoenv.2022.113330.


Applied machine learning in Alzheimer's disease research: omics, imaging, and clinical data.

Li Z, Jiang X, Wang Y, Kim Y Emerg Top Life Sci. 2021; 5(6):765-777.

PMID: 34881778 PMC: 8786302. DOI: 10.1042/ETLS20210249.


References
1.
Glant T, Besenyei T, Kadar A, Kurko J, Tryniszewska B, Gal J . Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models. Arthritis Rheum. 2013; 65(7):1725-35. PMC: 4102319. DOI: 10.1002/art.37986. View

2.
Chen B, Ding Y, Wild D . Assessing drug target association using semantic linked data. PLoS Comput Biol. 2012; 8(7):e1002574. PMC: 3390390. DOI: 10.1371/journal.pcbi.1002574. View

3.
Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth J, Mukhopadhyay T . The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 2002; 1(13):1201-9. View

4.
Furuya K, Kaku Y, Yoshida K, Joh K, Kurosaka D . Therapeutic effects of sunitinib, one of the anti-angiogenetic drugs, in a murine arthritis. Mod Rheumatol. 2013; 24(3):487-91. DOI: 10.3109/14397595.2013.844295. View

5.
ODell J, Haire C, Palmer W, Drymalski W, Wees S, Blakely K . Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1997; 40(5):842-8. DOI: 10.1002/art.1780400510. View